Financial Snapshot
Revenues
Revenues
Revenue YoY Change
Revenues
Expenses
Cost Of Revenues
Gross Profit
Gross Profit Margin
Gross Profit
Selling, General & Admin Expense
Research & Development
Depreciation, Depletion & Amortization
SGA Expense to Gross Profit Ratio
R&D To Gross Profit Ratio
DDA To Gross Profit Ratio
Operating Expenses Total
Operating Profits/Loss
Operational Expenses
Interest Expenses
Interest Expenses To Operating Income %
Other Expense/Income
Interest & Other Expense/Income
Income/Loss
Pretax Income
Income Tax
Net Profits/Loss
Pretax Income YoY Change
Income Tax Rate
Net Profits/Loss YoY Change
Basic EPS
Net Income To Revenue Ratio
Pretax & Net Income
Assets & Liabilities
Cash & Short-Term Investments
Cash & Equivalents
Cash To Operating Expenses Ratio
Inventory
Receivables
Total Short-Term Assets
Property, Plant And Equipment
Long-Term Investments
Total Long-Term Assets
Total Assets
Net Income To Total Assets Percentage
Accounts Payable
Short-Term Debt
Long Term Debt Due
Total Short-Term Liabilities
Long-Term Debt
Other Long-Term Liabilities
Total Long-Term Liabilities
Total Liabilities
Short-Term To Long-Term Debt Ratio
Short-Term Assets To Debt Ratio
Long-Term Debt To Net Income Ratio
Assets & Liabilities
Ownership
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares
Stock Issuance & Repurchase
Ownership Data
Return On Shareholders' Equity
Book Value
Free Cash Flow
Free Cash Flow YoY
Free Cash Flow Margin
Dividends
Dividends
Stock Price
About Clarus Therapeutics Holdings, Inc.
Clarus Therapeutics Holdings, Inc. is a pharmaceutical company, which engages in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is headquartered in Los Angeles, California and currently employs 16 full-time employees. The company went IPO on 2020-12-17. The firm is engaged in the development of androgen-based medicines. The firm is focused on the commercialization of JATENZO, which is an oral testosterone replacement or testosterone replacement therapy (TRT). JATENZO is a created by the linkage of T with the fatty acid undecanoic acid to form testosterone undecanoate. JATENZO is developed for T-replacement therapy to treat adult men with hypogonadism due to certain medical conditions. The company also focuses on the signs and symptoms associated with hypogonadism such as psychosexual symptoms, body mass index, fat mass and bone mineral density. The Company’s subsidiary is Clarus Therapeutics, Inc.
Industry: Biological Products, (No Diagnostic Substances) Peers: Kaya Holdings Inc Baudax Bio, Inc. Bespoke Extracts Inc Gelstat Corp Innovation1 Biotech Inc. Johnson & Johnson NEUROPATHIX, INC.
